Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM0G8XP)

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Dipeptidyl peptidase 4 (DPP-4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Saxagliptin	DMGXENV	Type-2 diabetes	5A11	Approved	[2]
Sitagliptin	DMGDKXN	Cystic fibrosis	CA25	Approved	[3]
Alogliptin	DM8WI3R	Type-2 diabetes	5A11	Approved	[4]
Linagliptin	DMWFJTR	Non-insulin dependent diabetes	5A11	Approved	[5]
Vildagliptin	DMYN59P	Type-2 diabetes	5A11	Approved	[6]
Dapagliflozin Propanediol; Saxagliptin Hydrochloride	DM34TXO	Type-2 diabetes	5A11	Approved	[7]
Anagliptin	DMJXIC9	Type-2 diabetes	5A11	Approved	[8]
SaxaDapa FDC	DMAPRWV	Diabetic complication	5A2Y	Phase 3	[9]
LC-150444	DM09RKB	Type-2 diabetes	5A11	Phase 3	[10]
Dutogliptin	DMM5VTA	Type-2 diabetes	5A11	Phase 3	[11]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

References

1	DPP-4 inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):209-36.
2	Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
3	Novel therapeutics for type 2 diabetes: incretin hormone mimetics (glucagon-like peptide-1 receptor agonists) and dipeptidyl peptidase-4 inhibitors. Pharmacol Ther. 2009 Oct;124(1):113-38.
4	Clinical pipeline report, company report or official report of Takeda (2009).
5	Boehringer Ingelheim. Product Development Pipeline. June 2 2009.
6	Emerging drug candidates of dipeptidyl peptidase IV (DPP IV) inhibitor class for the treatment of Type 2 Diabetes. Curr Drug Targets. 2009 Jan;10(1):71-87.
7	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
8	Diabetes Treatment. Diabetes Care. 2009 March; 32(3): e25-e30.
9	Saxagliptin: a new dipeptidyl peptidase-4 inhibitor for type 2 diabetes. Cardiol Rev. 2010 Jul-Aug;18(4):213-7.
10	Clinical pipeline report, company report or official report of ShangHai APIs Chemical.
11	Dutogliptin, a selective DPP4 inhibitor, improves glycaemic control in patients with type 2 diabetes: a 12-week, double-blind, randomized, placebo-controlled, multicentre trial. Diabetes Obes Metab. 2010 Apr;12(4):348-55.